HomeNewsBusinessEarningsCipla set to launch key drugs Abraxane and Advair in FY26
Trending Topics
Q2 Results Live
Bharti Airtel Q2 Results
Tata Consumer Q2 Results
Ambuja Cements Q2 Results
Bank of Baroda Q2 Results

Cipla set to launch key drugs Abraxane and Advair in FY26

Cipla's oncology drug Abraxane will be launched from its Goa facility while respiratory drug Advair will be rolled out from the New Jersey plant.

Vaibhavi Ranjan
January 28, 2025 / 16:55 IST
Story continues below Advertisement
Remove Ad
Cipla Q3 Results: The drugmaker topped the Street's estimates on all key parameters of profit, revenue and margins.
Cipla Q3 Results: The drugmaker topped the Street's estimates on all key parameters of profit, revenue and margins.
Vaibhavi Ranjan
first published: Jan 28, 2025 04:55 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.